The derivative 1-phenyl-2,5-dibenzimidazol-5-il-pyrolidine is an antiviral agent.
Patent Information
- Application Number
- TH1301001948
- Authority / Receiving Office
- TH · TH
- Patent Type
- Patents
- Current Assignee / Owner
- Filing Date
- 2011-10-12
- Publication Date
- 2026-10-02
- Estimated Expiration
- 2031-10-11
AI Technical Summary
Current NS5A inhibitors for Hepatitis C virus (HCV) treatment show reduced activity against certain HCV variants and poor pharmacokinetic properties, particularly when using non-aromatic heterocyclic linkers or unsubstituted benzimidazole moieties, which limits their effectiveness in inhibiting HCV replication.
Development of compounds with halo-substituted benzimidazole and pyrrolidinyl linkers, which improve anti-HCV activities and pharmacokinetic properties by enhancing the interaction with NS5A protein, specifically targeting HCV genotypes 1a and 2a, 2b, 3a, and 4a, and variants with specific mutations.
The compounds with halo-substituted benzimidazole and pyrrolidinyl linkers demonstrate significantly improved inhibitory activity against HCV genotypes 1a and 2a, 2b, 3a, and 4a, along with enhanced pharmacokinetic properties, such as increased plasma exposure, effectively reducing HCV levels in patients.